Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","sponsor":"PENDOPHARM DIVISION OF DE PHARMASCIENCE INC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

    Menu

    PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PENDOPHARM DIVISION OF DE PHARMASCIENCE INC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Health Canada Approval of Low-Dose Colchicine for Cardiovascular Disease Based on The COLCOT Study

              Details:

              Health Canada has issued a Notice of Compliance for the prescription drug MYINFLA™ (colchicine 0.5 mg tablets) based on the results of the Montreal Heart Institute (MHI)’s COLCOT clinical trial.

              Lead Product(s): Colchicine

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Myinfla

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Montreal Heart Institute

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 27, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY